OVERVIEW

Optimizing Integration of Bispecific Antibody Therapy to Improve Clinical Outcomes in Patients With Multiple Myeloma is organized by Decera Clinical Education and will be held on Aug 14, 2026.

Description:
The goal of this activity is to improve the knowledge, competence, and performance of learners in effort to optimize treatment for patients with Multiple Myeloma.

Learning Objectives
Upon completion of this activity, participants should be able to:

Educate patients and caregivers on the biologic rationale, mechanisms of action, administration, and treatment process for bispecific antibody therapy in R/R MM
Assess each patient’s eligibility and potential barriers to receiving bispecific antibodies that are approved or under investigation in R/R MM
Personalize treatment using approved or investigational bispecific antibodies for each eligible patient with R/R MM, considering available data, expert recommendations, and patient preferences
Implement effective workflow processes to monitor and manage bispecific antibody–related toxicities in patients with MM using the latest evidence and expert-recommended strategies
Develop plans for coordinating care among different specialists, departments, and/or centers to optimize each patient’s therapeutic benefit from bispecific antibody therapy for MM

KEY DATES

14 Aug, 2026

Event Start Date

14 Aug, 2026

Event End Date

ACCREDITATION & CREDITS

Credits:
Accreditation:
In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education:
Clinical Care Options, LLC dba Decera Clinical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development:
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Continuing Pharmacy Education:
Clinical Care Options, LLC dba Decera Clinical Education designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

Physician Associate Continuing Medical Education:
Clinical Care Options, LLC dba Decera Clinical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim commensurate with the extent of their participation.

American Board of Internal Medicine Maintenance of Certification:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

IPCE Credit Designation:
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

1 MOC

1 AMA PRA Category 1 Credit™

1 AAPA

1 CME

1 Contact Hours

0.1 CEUs

TARGET AUDIENCE

PhysicianPharmacistPhysician AssistantEmergency Medicine PhysiciansOncologistsHealthcare ProfessionalsNeurologistsHematologistInfectious Diseases PhysicianNurse Practitioners